Dopamine and Sensorimotor Function in Stuttering — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Dopamine and Sensorimotor Function in Stuttering — Stella

Recruiting

Back to Stuttering, Adult trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Biomagentic Imaging Lab, San Francisco, California

Key details

Phase

Early testing

Sponsor

University of California, San Francisco

Collaborators

National Institute on Deafness and Other Communication Disorders (NIDCD), University of Washington

Enrollment target

~40 participants

Started

September 2025

Primary completion

June 2026

Age range

18 Years – 65 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov